Neumora Therapeutics

Neumora Therapeutics Employees

5 people indexed:

Bill Aurora

Chief Strategy Officer

yd1k.284fkd@fss7hw11p.37h Sign up to see email

72gk.fpg02h@d78p242dq.hjq Sign up to see email
Joshua Pinto

Chief Financial Officer

7v13d7.k5zv9@q0fg4kf98.l7z Sign up to see email

1y9v67.by06b@q9q38fdgz.281 Sign up to see email
Mary Chamberlain-Tharp

Chief Business Officer

8j41.8z8sg78f6qz3v412d@70k7644w7.6s5 Sign up to see email

k84j.vfd26897v7k5s40vj@3z4g28016.5q1 Sign up to see email
Nick Brandon

Chief Scientific Officer

46y0.gsj0ss7@6vq904jfv.hz7 Sign up to see email

08fz.l2yg6z2@j5s9v28ly.220 Sign up to see email
Raj Manchanda

Chief Technical Operations Officer

21q.997v7g47b@2v07ybgg0.wk3 Sign up to see email

f42.917385f16@i034vp30p.pf0 Sign up to see email

Neumora Therapeutics Company Information

Neumora Therapeutics is at the forefront of developing precision medicines for brain diseases, leveraging recent scientific and technological advancements. The company’s approach integrates a Precision Toolbox that combines translational, clinical, and computational tools to innovate treatment solutions. Neumora’s therapeutic pipeline comprises seven programs aimed at addressing various neuropsychiatric disorders and neurodegenerative diseases. Their lead program, navacaprant, which is a kappa opioid receptor antagonist, is currently in Phase 3 clinical trials for major depressive disorder (MDD). With locations in the Greater Boston area and South San Francisco, Neumora Therapeutics is dedicated to addressing the global crisis of brain diseases affecting over 1.5 billion people worldwide.

Report inaccurate information